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Abstract The literature of the last 4 years confirms that the 
anti-CCP2 test is a very useful marker for the early and 
specific diagnosis of rheumatoid arthritis (RA). The anti- 
CCP2 test is very specific for RA (95-99%) and has 
sensitivity comparable to that of the rheumatoid factor (70­
75%). The antibodies can be detected very early in the 
disease and can be used as an indicator for the progression 
and prognosis of RA. In this review, these interesting 
properties and some future possibilities of this diagnostic 
test are discussed.
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The presence of autoantibodies in the serum of patients is a 
very typical phenomenon for autoimmune diseases. Most of 
these autoantibodies, however, can also be detected in 
patients with other conditions and are therefore not specific. 
A typical example is the rheumatoid factor (RF), which is 
present in most inflammatory conditions. However, in some 
cases, autoantibodies can give the clinician a more precise 
indication of the type of underlying disease because they 
occur specifically in a certain disease. For example, anti-Sm 
antibodies are linked almost exclusively to systemic lupus 
erythematosus (SLE); whereas anti-DNA topoisomerase-I 
antibodies are typically present in scleroderma patients. 
Among the most disease-specific autoantibodies described 
are the so-called ACPA (anti-citrullinated protein/peptide
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antibodies). These antibodies occur specifically in RA and 
can be measured most conveniently via the anti-CCP (anti- 
cyclic citrullinated peptide) antibody test.
The firstgenerationCCPtest(CCP1)usedin early diagnostic 
studies (2000-2001) contained a single cyclic citrullinated 
peptide derived from filaggrin as the substrate [1]. It could 
detect ACPA in 68% of patients with established RA with a 
very high specificity (98%). Because filaggrin is not 
expressed in the synovium, it is most likely not the natural 
citrullinated antigen for ACPA. Other peptides, not related 
to filaggrin, could therefore potentially provide better 
epitopes for detection of ACPA. Via screening of a number 
of peptide libraries, novel citrullinated peptides were 
obtained and incorporated into a second generation CCP 
test (CCP2). This test is commercially available, and as all 
companies use the same type of CCP2 peptides, standard­
ization is achieved quite easily. The diagnostic properties of 
this test will be discussed below.
The CCP2 Test is Sensitive and Highly Specific for RA
Since its appearance on the market in the second half of 
2002, the diagnostic properties of the CCP2 test have been 
studied by many laboratories. This resulted in more than 
120 publications dealing with this subject. The accumulated 
data, including only papers that appeared in PubMed till 
December 2006, are given in Table 1. It is clear that the 
accumulated data confirm the earliest reports on specificity 
and sensitivity of the CCP2 test. The anti-CCP2 test 
demonstrates an RF-like sensitivity with a very high 
specificity for RA (see also recent reviews: [2, 3]). It is 
also commonly recognized that anti-CCP2 antibody may be 
present in up to 40% of RF-negative RA sera [4, 5].
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Table 1 Cumulative anti-CCP2 
diagnostic data published 
between 2002 and 2006
In total, 122 independent studies 
were included. The selection 
for early RA has been adopted 
from the original reports.
Patient group Number CCP2+ Sensitivity (%) Specificity (%)
RA total 14,183 10,135 71.5
Early 3,876 2,365 61.0
Established 10,307 7,770 75.4
Controls 15,156 683 4.5 95.6
Non-RA 11,502 647 5.6 94.4
Healthy 3,654 36 1.0 99.0
The anti-CCP2 test enables clinicians to distinguish RA 
patients from other arthritic diseases, especially in cases 
where the RF test is not discriminative. This is, for 
example, the case with chronic hepatitis C virus (HCV) 
infection, a disease that can easily be misdiagnosed as it 
often reveals RA-like arthropathies and, in many cases, is 
accompanied by a positive RF. Several examples of such 
studies are given in recent reviews on this subject [6].
Recently, there is also an interest to compare the 
diagnostic potential of anti-CCP2 with novel tests based 
on the use of a citrullinated antigen (for example, MCV= 
anti-mutated citrullinated vimentin [7], CPA=citrullinated 
protein antibodies, VCP=anti-viral citrullinated protein [8], 
antihuman fibrinogen alpha [9, 10], and CCP3 [11]). For a 
reliable comparison of these tests, it is essential that their 
performance is assessed under the same conditions, e.g., the 
sensitivities of the tests should be determined at the same 
level of specificity. Good examples of such stratified 
studies have been carried out recently by van der Cruijssen 
et al. [10] and Dejaco et al. [7]. For example, Dejaco et al. 
[7] showed, in a large cohort of patients (>600), that at a 
specificity of 98.7%, being the specificity of the anti-CCP2 
test, the sensitivity of the anti-MCV test is 53.7% as 
opposed to 70.1% for the anti-CCP test. Coenen et al. [11] 
compared several commercial tests, including a very recent 
CCP3 test from Inova. At the cut-offs recommended by the 
various manufacturers, the positive predictive value of the 
three commercial CCP2 tests is about 90% with a 
specificity of around 96%. The specificity of the other tests 
(CCP3=88%, MCV=90%, CPA=94%) is lower as are their 
positive predictive values [11]. These numbers may 
improve a little bit when the cut-off values are adjusted to 
more realistic data; nevertheless, the data allow the statement 
that, in absolute percentages, none of the tests performs better 
than the anti-CCP2 test. They also seem to indicate that some 
tests detect RA patient groups that are negative in the anti- 
CCP test, illustrating again that the autoantibody repertoire of 
RA patients is very heterogeneous.
Another risk for the specificity of a test that is based on a 
citrullinated antigen is the possibility that antibodies are not 
directed exclusively to the citrulline-containing epitope but 
also to other possibly overlapping epitopes present in the
substrate antigen. This is particularly important when 
citrullinated versions of proteins like vimentin or fibrinogen 
are used. For example, it is known that antibodies to 
vimentin are present in several diseases different from RA 
[12, 13]. This particular problem has been addressed for 
CCP2 by Vannini et al. [14]. They used ELISA plates 
containing the control CCP2 antigens (Arg instead of Cit in 
the same peptide context), produced and made available by 
Euro-Diagnostica, Arnhem, The Netherlands, in parallel to 
the normal CCP2 test. The results of these comparative 
studies showed that in RA and most non-RA rheumatic 
disease sera, anti-CCP reactivity indeed is citrulline- 
dependent. However, in some patients, particularly autoim­
mune hepatitis patients, citrulline-independent reactivity 
with the antigen may occur. A positive CCP test in a 
rheumatic disease (almost always citrulline-specific) may 
thus suggest the future development of RA as has been 
suggested by several studies [15, 16]. A positive test in a 
nonrheumatic disease (very often not citrulline-specific), for 
example, liver disease, should be interpreted with care [14].
Anti-CCP2 Antibodies are Present Early in Disease 
and have Predictive Potential
Because RA patients at first presentation often do not fulfill 
the criteria for the diagnosis/classification of RA, an early, 
highly predictive marker would greatly assist the clinician 
in reaching an early diagnosis. There are several studies 
indicating that the anti-CCP2 test provides this help 
(reviewed by [2]).
In the recently published EULAR recommendations fo r  
the management of early arthritis [16], a list of factors has 
been proposed that predict persistent and erosive disease. 
These factors include: number of swollen and tender joints, 
ESR or CRP, level of RF and anti-CCP antibodies, and 
radiographic erosions. Most of these factors were also 
mentioned as being important in the prediction of early 
erosive RA (Visser et al. [17]). Subsequent studies by the 
same group gave an indication of the relative importance of 
these factors. When expressed as odds ratios (OR), the data 
was as follows: arthritis of three or more joints, 5.0;
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radiographic erosions, 8.7; positive IgM-RF, 1.7; and 
positive anti-CCP2, 38.6 [18]. These and other data (see 
also [19]) clearly show that the presence of anti-CCP 
antibodies is an important and independent prognostic 
factor for radiographic progression in not only early 
arthritis but also in early rheumatoid arthritis [16, 20].
Recently, it has also been shown that IgM-CCP is 
present in early samples from both patients with undiffer­
entiated arthritis (UA) and patients with RA as well as in 
follow-up samples from patients with RA. These data 
indicate the development of the anti-CCP isotype repertoire 
into full usage early in the course of arthritis and a 
continuous (re)activation of the RA-specific anti-CCP 
response during the further development of the disease [21].
It is, however, evident that besides the clinical and 
laboratory parameters mentioned above, some genetic 
factors are important as well. The effect of the HLA 
shared-epitope alleles on the development of ACPA has 
been firmly established. Citrullination is typically a process 
that occurs in apoptotic cells. Because such dying cells are 
generally removed from the environment via clearance by 
phagocytes, a process that is regulated by many genes, the 
immune system will normally not encounter citrullinated 
proteins. However, it has been shown that during inflam­
mation, citrullinated proteins are detectable in the inflamed 
tissue, both in RA and non-RA patients [22]. This is 
probably caused by inefficient clearance of the massive 
numbers of dying cells, a process already described to 
occur in SLE [23]. This inefficient clearing could, in 
principal, also be the consequence of altered genes, i.e., 
the genetic background. The mere presence of citrullinated 
antigens in inflamed synovial tissue does not necessarily 
result in the occurrence of anti-CCP antibodies in serum or 
synovial fluid, neither in humans nor in mouse models of 
arthritis [24, 22]. Hill et al. [25] showed that the generation 
of anticitrulline antibody in mice actually is linked to the 
expression of the RA shared epitope (SE), and a similar link 
was also found in patients because the combination of SE, 
and anti-CCP has a very high predictive value for the future 
development of RA [26]. The specific structure of HLA 
molecules obviously plays an important role in the 
induction of autoimmunity to citrullinated proteins. These 
studies were extended by Huizinga et al. [27] who found 
that HLA-DRB1 alleles encoding the SE were only 
associated with anti-CCP positive RA and not with anti- 
CCP negative RA. In contrast, anti-CCP negative RA 
appeared to be associated with HLA-DR3 [28]. Therefore, 
the presence of citrullinated antigens, together with the 
appropriate genetic background (the SE and probably other 
types of HLA), appears to be the minimum requirement for 
an immune response to citrullinated polypeptides to be 
generated [29]. Next to that, other sensitizing genetic 
settings resulting from polymorphisms (e.g., PTPN22
[30]) might, given their association, aid in triggering of 
ACPA.
Conclusions and Future Perspectives
The present literature describes and confirms that the anti- 
CCP2 test is a very useful marker for the early and accurate 
diagnosis of RA. Anti-CCP antibody is very specific for 
RA and has a sensitivity comparable to that of RF. These 
antibodies can be detected very early in disease and may be 
used as an indicator for the progression and prognosis of 
RA. Initially, the test was available principally as a manual 
ELISA method through Euro-Diagnostica and Axis-Shield 
and their partners. More recently, fully automated anti-CCP 
assays have also been made available from Phadia (UniCap 
Elia CCP) and Abbott Diagnostics (AxSYM anti-CCP). A 
very novel format is the CCPoint, a Point-of-Care test for 
the detection of these antibodies in whole blood in 10 min
[31]. A small drop of whole blood is applied onto the 
sample well followed by the addition of four drops of 
running buffer. After 10 min, the result is read by visual 
inspection of the detection zone for staining of the antigen 
line. As no special equipment is required to perform the 
assay, this test will bring the detection of anti-CCP 
antibodies into the office of the family doctor, facilitating 
a very fast referral to the rheumatologist when the test gives 
a positive answer. Such new applications will undoubtedly 
further enhance the utility of the anti-CCP autoantibody 
system in clinical practice.
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